

















  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A - Full Text View - ClinicalTrials.gov</title>
    <link href="/ct2/show/NCT03020160" rel="canonical"/>
    
  <!-- Twitter Card data -->
  <meta name="twitter:card" content="summary">
  <meta name="twitter:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">

  <!-- Open Graph data -->
  <meta property="og:type" content="article" />
  <meta property="og:title" content="A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A - Full Text View - ClinicalTrials.gov">
  <meta property="og:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">
    <meta property="og:description" content="A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A - Full Text View.">
  <meta property="og:url" content="https://clinicaltrials.gov/ct2/show/NCT03020160">
    
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish-vertical.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/glossary.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/base.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/print.css?v=44" media="print" />
  <link rel="stylesheet" href="/ct2/html/css/w3-ct.css?v=44" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/css/w3-ct-oldIE.css?v=44" type="text/css" />
  <![endif]-->
   	
  <link rel="preconnect" href="https://use.fontawesome.com">
  <link rel="preconnect" href="https://www.ncbi.nlm.nih.gov">
  
  <script src="https://use.fontawesome.com/20a31629ec.js"></script>
<!--[if lte IE 7]>
       <link href="/ct2/html/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
<![endif]-->

<style type="text/css">
  h2 
  {
      background-color: #EAEAEA;
  }
</style>
<link href="/ct2/html/css/trial-record.css?v=44" rel="stylesheet" type="text/css" />

	<script type="text/javascript" src="/ct2/html/jquery/js/jquery.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/jquery/js/superclick.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ct.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ctmenu.js?v=44"></script><noscript></noscript>
<script>
var theURL = "/ct2/show/NCT03020160"+window.location.hash;
history.replaceState(null,null,theURL);
</script>

  <meta name="ncbi_sid" content="4ec8b7bc0e309146_36c1a9SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_study"/>
  <meta name="ncbi_pcid" content="NCT03020160"/>
  <meta name="ncbi_ctreqid" content="R990F27z"/>
  <meta name="ncbi_ctsessid" content="S990Dl4A"/>
  <meta name="ncbi_ctipid" content="IZ45kPwP"/>
  <meta name="ncbi_cthost" content="w12"/>
</head>


<body> 
<script type="text/javascript">
    jQuery.getScript("https://www.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
      galert(['#alert_banner', 'body &gt; *:nth-child(1)'])});
</script>

<div id="alert_banner"></div>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<script type='text/javascript'>
(function(){var g=function(e,h,f,g){
this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
try{(new g(100,"r","QSI_S_ZN_7WHWRcRMBs9xWYd","https://zn7whwrcrmbs9xwyd-nlmenterprise.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_ZID=ZN_7WHWRcRMBs9xWYd")).start()}catch(i){}})();
</script><div id='ZN_7WHWRcRMBs9xWYd'><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END WEBSITE FEEDBACK SNIPPET-->
<div id="glossary" class="glossary"
    aria-describedby="glossary-result" aria-hidden="true">
  <button
      title="Close glossary"
      class="js-glossary-close button button--close js-glossary-toggle usa-button-unstyled"
    ><span class="usa-sr-only">Hide glossary</span>
    <i class="fa fa-times" aria-hidden="true"></i>
  </button>
  <h4 class="glossary-heading">Glossary</h4>
  <p>
  Study record managers: refer to the <a href="https://clinicaltrials.gov/ct2/manage-recs/resources#DataElement"><span style="text-decoration:underline">Data Element Definitions</span></a> if submitting registration or results information.
  </p>
  <p>
  <label for="glossary-search" class="label">Search for terms</label>
  </p>
  <span class="clearable-input">
  <input id="glossary-search" class="js-glossary-search">
   <span data-clear-input="" class="js-glossary-clear button js-glossary-toggle usa-button-unstyled">x</span>
  </span>
  <div class="glossary__content" id="glossary-result">
    <ul class="js-glossary-list"></ul>
  </div>
</div>

<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>


<script type="text/javascript" src="/ct2/html/js/working.js"></script><noscript></noscript>
<div id="workingDim" class="ct-dim">
  <div id="workingIndicator" class="ct-workingBox" style="text-align:center;vertical-align:middle;">
    <img alt="Working&#8230;" src="/ct2/html/images/working.gif" height="50" >
  </div>
</div>

<div id="wrapper"> 
<div class="ct-inner_wrapper">   			<a href="/ct2/home" style='float:left;border-bottom-width:0;min-width:200px;width:29%;'><img src='/ct2/html/images/ct.gov-nlm-nih-logo.png' alt='ClinicalTrials.gov'/></a>

				<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
								</ul>
				</div>
    		</div>
  		</div>		
		
<div 
style="float:right;margin-top:1.5%;" 
class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
				<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
				</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div>

</div> 
<div class="ct-outer_breadcrumb w3-container">
	<div id="breadcrumb">
    <ul class="ct-horz-list w3-left">
			<li><a href="/ct2/home">Home</a></li>
												<li><a href="/ct2/results">Search Results</a></li>
										<li>Study Record Detail</li>
    </ul>
    <div id="savedStudies" class="w3-right">
  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
  	<button class="ct-savedStudiesEnabled" id="open-cart-link" type="button" 
  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
  		title="Show previously saved studies.">Saved Studies</button>
  	</div>
</div>
<script type="text/javascript" src="/ct2/html/js/cart.js?v=44"></script><noscript></noscript>

		<script type="text/javascript">
	$(document).ready(function(){
		$("input#saved").prop( 'checked', (inCart("NCT03020160")>=0));
	});
</script>
		<div class="w3-right" style="margin-right: 1em;">
			<label for="saved" title="Add or Remove this study in the Saved Studies list"><input type="checkbox" id="saved" name="NCT03020160" onchange="updateCart('NCT03020160');" style="margin-left:1em;"> Save this study </label>
		</div>
		<div id="maxSavedStudies-popup" class="w3-modal" style="cursor:pointer;border:2px groove" onclick="$('#maxSavedStudies-popup').hide();">
	<div id="maxSavedStudies-popup-content" class="w3-modal-content">
		<div class="w3-display-container" style="border:1px solid #ccc;background-color:#eee;">
			<form>
			<div class="w3-center" style="font-size:large;font-weight:bold;padding:3ex 1.5em;">
				<img src="/ct2/html/images/warning.png" alt="Maximum Saved Studies Reached" style="max-width:1.0rem;cursor:pointer;"/>
			    <b>Warning</b>
				<div style="margin-top:1ex;margin-bottom:0.5ex;">You have reached the maximum number of saved studies (100).</div>
				<div>Please remove one or more studies before adding more.</div>
			</div>
		
			<div class="w3-center" style="padding-bottom:1.5ex">
			  <input class="ct-searchButton" type="button" style="opacity:1.0;font-weight:bold;font-size:inherit;padding:1.1ex 1em;" onclick="$('#maxSavedStudies-popup').hide();" value="Close" title="Close this dialog"/>
			</div>
			</form>
		</div>
	</div>
</div>

	</div>
</div>

<div style="clear:both;"></div>

<div id="main-content" tabindex='-1'>
	
	
		<div class="tr-indent2">
        	<h1 class="tr-h1 ct-sans-serif tr-solo_record">A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)</h1>

  <div class="w3-row">
    <div class="w3-col m6">       <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tr>
            <td style="width:5%">
              <img src="/ct2/html/images/warning.png" style="width:1.3em;" alt=""/>
            </td>
            <td style="padding-right:2em;">
              The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT03020160</div>
-->
  <div class="w3-col m1">&nbsp;</div> 
  <div class="w3-col m5">   <table style="width:95%">
  <tr><td>ClinicalTrials.gov Identifier: NCT03020160</td>
  </tr>
  <tr><td>
      
       
              <div  class="tr-status tr-not-recruiting-colors" >
                        <span style="display:inline;" class="term" data-term="Recruitment Status" title="Show definition">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="Recruitment Status" style="border-bottom-style:none;"></i></span> : 
                    Active, not recruiting
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="First Posted" title="Show definition">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="First Posted" style="border-bottom-style:none;"></i></span> : January 13, 2017</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="Results First Posted" title="Show definition">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Results First Posted" style="border-bottom-style:none;"></i></span> : December 26, 2018</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="Last Update Posted" title="Show definition">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Last Update Posted" style="border-bottom-style:none;"></i></span> : May 17, 2021</div>

  
      </div>
  </td>
  </tr>
  </table>
  </div>
  </div>


                <div class="tr-info-title">Sponsor:</div>
                <div class="tr-info-text" id="sponsor"> Hoffmann-La Roche </div>
                <div class="tr-info-title">Collaborator:</div>
                                  				  				                                    <div class="tr-info-text" id="sponsor1">Chugai Pharmaceutical</div> 
                  				  
                              <div class="tr-info-title">Information provided by (Responsible Party):</div>
                <div class="tr-info-text" id="responsibleparty">Hoffmann-La Roche</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"  class="current">Study Details     </li>
		<li id="tabular"   ><a href="/ct2/show/record/NCT03020160" >Tabular View</a></li>
  					<li id="results"   ><a href="/ct2/show/results/NCT03020160">Study Results</a></li>
						<li id="disclaimer"><a title="Disclaimer - opens new window"  href="/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false"
>Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->
		
	<div id="tab-body">
		<div class="tr-indent2" style="background-color:white;">
						  
<!-- purpose_section -->
<div class="tr-indent1" style="margin-top:1ex">

<div class="tr-subsection">
	<div class="ct-header2"><a id="studydesc"></a>Study Description</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

<div class="tr-indent2" style="margin-top:2ex">

  <div class="ct-body3">Brief Summary:</div>
  <div class="ct-body3 tr-indent2">This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks in participants with hemophilia A with or without inhibitors against factor VIII (FVIII). The study consists of 2 parts: a pharmacokinetic (PK) run-in part followed by an expansion part.</div><br/>

    <!-- condition, intervention, phase summary table -->
  <table class="ct-data_table tr-data_table" border="1" style="margin:auto;width:80%;">
    <tr style="text-align:left;">
            <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Condition/disease" title="Show definition">Condition or disease <i class="fa fa-info-circle term" aria-hidden="true" data-term="Condition/disease" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Phase" title="Show definition">Phase <i class="fa fa-info-circle term" aria-hidden="true" data-term="Phase" style="border-bottom-style:none;"></i></span>       </th>
          </tr>
    <tr style="text-align:left;vertical-align:top;">
            <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Hemophilia A</span>
              </td>
                  <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Drug: Emicizumab</span>
              </td>
                  <td class="ct-body3" style="white-space:nowrap;">
                <span style="display:block;margin-bottom:1ex;">Phase 3</span>
              </td>
          </tr>
  </table>
  <br/>
  
  
  </div> 
<div class="tr-subsection">
  <div class="ct-header2"><a id="studydesign"></a>Study Design</div>
  <div class="tr-underline"></div>
  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

  <p>
  <table class="ct-layout_table tr-tableStyle tr-studyInfo" style="margin-bottom:2ex;">
   <caption>Layout table for study information</caption>
   <thead>
    <tr>
      <th id="studyInfoColTitle"></th>
      <th id="studyInfoColData"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="studyInfoColTitle">
<span style="display:inline;" class="term" data-term="Study Type" title="Show definition">Study Type <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Type" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">
        Interventional
                &nbsp;(Clinical Trial)
                
        
      </td>
    </tr>
                    <tr>
      <td headers="studyInfoColTitle">Actual
<span style="display:inline;" class="term" data-term="Enrollment" title="Show definition">Enrollment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Enrollment" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">48 participants</td>
    </tr>
                <tr>
            <td headers="studyInfoColTitle">Allocation:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Non-Randomized</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Intervention Model:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Parallel Assignment</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Masking:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> None (Open Label)</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Primary Purpose:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> Prevention</td>
    </tr>
                    <tr>
<!--
      <td headers="studyInfoColTitle" style="padding-top:2ex;">Official Title:</td>
-->
      <td headers="studyInfoColTitle">Official Title:</td>
      <td headers="studyInfoColData" style="padding-left:1em;">A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A</td>
    </tr>
    
            <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Start Date" title="Show definition">Study Start Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Start Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">January 30, 2017</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Primary Completion Date" title="Show definition">Primary Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">December 15, 2017</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Estimated <span style="display:inline;" class="term" data-term="Study Completion Date" title="Show definition">Study Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">June 30, 2022</td>
      </tr>
            </tbody>
    </table>

    <!-- NLM links -->
<p>
<div class="tr-indent2">
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Resource links provided by the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>

    <!-- ghr links -->
  <div style="margin-bottom:2ex">
    <a class="tr-study-link" href="https://medlineplus.gov/genetics/" title="MedlinePlus Genetics" onclick="openNewWindow('https://medlineplus.gov/genetics/'); return false">MedlinePlus Genetics</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/genetics/condition/hemophilia" title="Hemophilia at Genetics Home Reference" onclick="openNewWindow('https://medlineplus.gov/genetics/condition/hemophilia'); return false">Hemophilia</a>
	          </div>
  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://medlineplus.gov/" title="MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/'); return false">MedlinePlus</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/hemophilia.html" title="Hemophilia at MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/hemophilia.html'); return false">Hemophilia</a>
	          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://druginfo.nlm.nih.gov/drugportal" title="Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal'); return false">Drug Information</a> available for:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab" title="Emicizumab at Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab'); return false">Emicizumab</a>
	          </div>
  
    <!-- ORD links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://rarediseases.info.nih.gov/gard" title="Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/gard'); return false">Genetic and Rare Diseases Information Center</a> resources:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/10418/hemophilia" title="Hemophilia at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/10418/hemophilia'); return false">Hemophilia</a>
	        	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a" title="Hemophilia&#160;A at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a'); return false">Hemophilia&#160;A</a>
	          </div>
  
  
  <!-- Ropr Link -->
<!-- Commented out RoPR
  -->

  <div style="margin-bottom:2ex;">
  <a class="tr-study-link" href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>
  </div>

  </div>
</div>


  
  <br/>
    </div>

    <!-- arms and groups table -->
    		<div class="tr-subsection">
		    		    	<div class="ct-header2"><a id="armgroup"></a>Arms and Interventions</div>
		    		    <div class="tr-underline"></div>
			<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
		</div>
	
    <div style="padding-left:.8em; padding-right:1.2em;text-align:left;">
        <p>
    <table class="ct-data_table tr-data_table" style="padding:5px;width:100%;border-width:1px;">
      <thead>
      <tr style="text-align:left;">
        <th class="ct-header3 tr-pale_banner_color" style="width:50%;">
            				<span style="display:inline;" class="term" data-term="Arm" title="Show definition">Arm <i class="fa fa-info-circle term" aria-hidden="true" data-term="Arm" style="border-bottom-style:none;"></i></span> 			        </th>
                <th class="ct-header3 tr-pale_banner_color">
			<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>         </th>
              </tr>
      </thead>
      <tbody>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Emicizumab: Expansion Part
<div class="tr-indent2" style="margin-top:0.5ex">Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered according to dose and schedule described in respective arms. Upon implementation of protocol Version 5, treatment duration will be extended. During this study prolongation, participants will have the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: Emicizumab: PK Run-in Part
<div class="tr-indent2" style="margin-top:0.5ex">Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Emicizumab will be administered according to dose and schedule described in respective arms. Upon implementation of protocol Version 5, treatment duration will be extended. During this study prolongation, participants will have the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            </tbody>
    </table>
          </div>
    <br/>

    
    <!-- more details -->
  <br/>
  <div class="tr-subsection">
	  <div class="ct-header2"><a id="outcomemeasures"></a>Outcome Measures</div>
	  <div class="tr-underline"></div>
	  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  <br/>
  <div class="tr-indent3" style="margin-right:1em;">

        <!-- primary outcomes -->
    <div class="ct-body3">
<span style="display:inline;" class="term" data-term="Primary Outcome Measure" title="Show definition">Primary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            	<li style="margin-top:0.7ex;">Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As &quot;all bleeds&quot; comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the &quot;treated bleeds&quot; outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.</div><br/>
            	<li style="margin-top:0.7ex;">Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.</div><br/>
            	<li style="margin-top:0.7ex;">Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;joint bleed&quot; is defined as a bleed with type reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A &quot;treated joint bleed&quot; is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of joint bleeds, excluding bleeds due to surgery/procedure.</div><br/>
            	<li style="margin-top:0.7ex;">Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A &quot;target joint bleed&quot; is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A &quot;treated target joint bleed&quot; is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.</div><br/>
            </ol>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="ct-body3"  style="margin-right:1em;">
<span style="display:inline;" class="term" data-term="Secondary Outcome Measure" title="Show definition">Secondary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Secondary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (&#8805;18 Years of Age) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a &quot;not applicable&quot; option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Percentage of Adult Participants (&#8805;18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a &quot;not applicable&quot; option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (&#8805;18 Years of Age) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a &quot;not applicable&quot; option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Percentage of Adult Participants (&#8805;18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a &quot;not applicable&quot; option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age) [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haemo-QoL-SF was developed in a series of age-related questionnaires to measure health-related quality of life (HRQoL) in children and adolescents with hemophilia. The short version for older children containing 35 items was selected for adolescents in this study. Items are rated along five response options: never, rarely, sometimes, often, or all the time. This version covers nine dimensions considered relevant for the children's HRQoL (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia, and treatment). Scale scores range from 0 to 100, with lower scores indicating better HRQoL. Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Proportion of Days Away From Work to Expected Days at Work in the Previous Four Weeks [&nbsp;Time&nbsp;Frame:&nbsp;Predose at Baseline, Weeks 13 and 25, and every 12 weeks thereafter up to study completion/early termination (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Participants enrolled in the expansion part of the study reported at each time point the number of days away from work (i.e., days of work missed) and the expected number of days at work in the previous four weeks, which is reported here for each time point as the proportion of the number of days away from work to the expected number of days at work.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Proportion of Days Away From School to Expected Days at School in the Previous Four Weeks [&nbsp;Time&nbsp;Frame:&nbsp;Predose at Baseline, Weeks 13 and 25, and every 12 weeks thereafter up to study completion/early termination (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Participants enrolled in the expansion part of the study reported at each time point the number of days away from school (i.e., days of school missed) and the expected number of days at school in the previous four weeks, which is reported here as the proportion of the number of days away from school to the expected number of days at school.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Number of Days Hospitalized [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline until at least 24 weeks of treatment through to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks); all participants had completed at least 24 weeks of treatment.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Percentage of Participants Who Preferred Either the New Emicizumab Subcutaneous (SC) Treatment or Their Previous Hemophilia Intravenous (IV) Treatment, or Had No Preference, as Assessed Using the Emicizumab Preference Survey [&nbsp;Time&nbsp;Frame:&nbsp;Predose at Week 17&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with intravenous (IV) factor VIIII (FVIII) or subcutaneous (SC) emicizumab, or no preference.</div><br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Maximum Observed Plasma Concentration (Cmax) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Apparent Plasma Terminal Half-Life (t1/2) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">PK Run-In Part: Apparent Clearance (CL/F) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (0 hr) and 8 hrs postdose on Day 1; Days 3,5,8,11,15,18,22,25,29,36,43,50,57,85,113,141,148,155,162,169, once between 2 emicizumab administrations between Weeks 9 and 21, and once every 12 weeks from Week 25 to study completion (up to 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Only CL/F is reported after the first dose; the apparent clearance at steady state (CLss/F) is reported after the sixth dose instead. This is because t1/2 was not properly estimated after the first dose due to sampling time and dosing schedule, and dependent PK parameters, such as CL/F, could not be estimated.</div><br/>
            <li style="margin-top:0.7ex;">Expansion Part: Minimum Observed Plasma Concentration (Cmin) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, and once every 12 weeks from Week 25 to study completion (up to approximately 4 years)&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Number of Participants With At Least One Adverse Event [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Grade &#8805;3 Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Adverse Events Leading to Withdrawal From Treatment [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Adverse Events of Changes From Baseline in Vital Signs [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Adverse Events of Changes From Baseline in Physical Examination Findings [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Adverse Events of Abnormal Laboratory Values [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;"><p style="margin-top:0ex; margin-bottom:1ex;">The number of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</p></div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Local Injection-Site Reactions [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an &quot;injection-site reaction&quot; on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a &quot;local injection-site reaction.&quot; At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Thromboembolic Events [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Thrombotic Microangiopathy [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With Anti-Drug Antibodies to Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 5, 9, 13, 17, 21, and 25, and every 12 weeks thereafter until study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">A validated ELISA method was used to analyze the levels of anti-drug antibodies to emicizumab in blood plasma samples. A sample was considered positive for anti-drug antibodies if the test result reached or exceeded a pre-determined threshold. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            <li style="margin-top:0.7ex;">Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 9 and 17 (for non-inhibitor subjects only), Week 25, and every 12 weeks thereafter until study completion (up to approximately 4 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold. At the clinical cut-off date for primary analysis (15 Dec 2017), the median observation time was 43.71 weeks (range: 41.7-45.7 weeks).</div><br/>
            </ol>
    </div>
    <br/>
    
    
    
  </div>
  
			  
<!-- eligibility_section -->
<div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
<div class="tr-subsection">
	<div class="ct-header2"><a id="eligibility"></a>Eligibility Criteria</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>

<p>
  <div class="tr-indent2 usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a href="/ct2/about-studies/learn" title="Learn About Clinical Studies"><u>Learn About Clinical Studies.</u></a>
    </em>
  </div>


  <br/>
  <div class="tr-indent2">
    <table class="ct-layout_table tr-tableStyle tr-studyInfo">
      <caption>Layout table for eligibility information</caption>
      <thead>
        <tr>
          <th id="elgType"></th>
          <th id="elgData"></th>
        </tr>
      </thead>
      <tbody>
            <tr>
        <td headers="elgType" class="ct-nowrap">Ages Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">12 Years and older &nbsp; (Child, Adult, Older Adult)</td>
      </tr>
                  <tr>
        <td headers="elgType" class="ct-nowrap">Sexes Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">All</td>
      </tr>
                              <tr>
        <td headers="elgType" class="ct-nowrap">Accepts Healthy Volunteers: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">No</td>
      </tr>
                  </tbody>
    </table>

    
        <div class="ct-header3" style="margin-top:2ex">Criteria</div>
    <div class="tr-indent2"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Body weight greater than or equal to (&gt;/=) 40 kilograms (kg) at screening</li>
    <li style="margin-top:0.7ex;">Diagnosis of severe congenital hemophilia A or hemophilia A with FVIII inhibitors</li>
    <li style="margin-top:0.7ex;">Participants using rFVIIa or willing to switch to recombinant activated factor VII (rFVIIa) as primary bypassing agent for the treatment of breakthrough bleeds</li>
    <li style="margin-top:0.7ex;">FVIII inhibitor test during screening with titer results available prior to first administration of study drug</li>
    <li style="margin-top:0.7ex;">Participants without FVIII inhibitors, that is with less than (&lt;) 0.6 Bethesda unit per milliliter [BU/mL];&lt; 1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL, who completed successful immune tolerance induction (ITI) must have done so at least 5 years before screening and must have no evidence of inhibitor recurrence (permanent or temporary) indicated by detection of an inhibitor greater than (&gt;) 0.6 BU/mL (&gt; 1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) since ITI</li>
    <li style="margin-top:0.7ex;">Adequate hematologic, hepatic, and renal function</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Inherited or acquired bleeding disorder other than hemophilia A</li>
    <li style="margin-top:0.7ex;">Ongoing or planned ITI therapy; participants in whom ITI has failed will be eligible with a 72-hour washout period prior to the first emicizumab administration</li>
    <li style="margin-top:0.7ex;">History of illicit drug or alcohol abuse within 48 weeks prior to screening, in the investigator's judgment</li>
    <li style="margin-top:0.7ex;">Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment</li>
    <li style="margin-top:0.7ex;">Previous (within the last 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease</li>
    <li style="margin-top:0.7ex;">Other conditions (for example, certain autoimmune diseases) that may currently increase the risk of bleeding or thrombosis</li>
    <li style="margin-top:0.7ex;">History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection</li>
    <li style="margin-top:0.7ex;">Known HIV infection with cluster of differentiation (CD) 4 cells counts &lt;200 cells per microliter (cells/mcL)</li>
    <li style="margin-top:0.7ex;">Use of systemic immunomodulators (for example, interferon) at enrollment or planned use during the study, with the exception of anti-retroviral therapy</li>
    <li style="margin-top:0.7ex;">Concomitant disease, condition, significant abnormality on screening evaluations or laboratory tests, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an additional unacceptable risk in administering study drug to the participant</li>
    <li style="margin-top:0.7ex;">Pregnancy or lactation or intention to become pregnant during the study</li>
    <li style="margin-top:0.7ex;">Women with a positive serum pregnancy test result within 7 days prior to initiation of study drug</li>
  </ul></div>
    
  </div>

  </div>

			  
<!-- location_section -->
<a id="contacts"></a>
<div class="tr-indent1" style="margin-top:3ex">
<div class="tr-subsection">
	<div class="ct-header2"><a id="contactlocation"></a>Contacts and Locations</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>


<div class="tr-indent2" style="margin-top:2ex">

<!--
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 
For general information, see <a href="/ct2/about-studies/learn" target="def_win" onClick="openNewWindow('/ct2/about-studies/learn'); return false;" title="Learn About Clinical Studies - opens new window"><u>Learn About Clinical Studies.</u></a>
<br/>
-->

  
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>
    To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
    </em>
    <p>
    <em>
    Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT03020160</strong>
    </em>
  </div>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
   <a id="locn"></a>
  <div class="ct-header3" style="margin-top:2ex;margin-bottom:2ex;">Locations</div>

      <script type="text/javascript" async src="/ct2/html/js/ExpandCollapseScript.js"></script>
    
    <span id="EXPAND_CONTROL-Locations" class="EXPAND tr-showAndHide"       onclick="toggleSectionAndControls('-Locations');document.getElementById('locn').scrollIntoView({behavior: 'smooth', block: 'start'});" 
      title="Show 17 study locations">
      <img src="/ct2/html/images/expand.png" alt="Show">
      <span style="padding-bottom:3px"> Show 17 study locations</span>
    </span>
    <span  id="COLLAPSE_CONTROL-Locations" class="COLLAPSE tr-showAndHide" style="display:none"      onclick="toggleSectionAndControls('-Locations');" 
      title="Hide 17 study locations">
      <img src="/ct2/html/images/collapse.png"  alt="Hide">
      <span style="padding-bottom:3px"> Hide 17 study locations</span>
    </span>
     
  <div id="COLLAPSE-Locations" class="COLLAPSE" style="display:none">
        <div class="tr-table_cover">
      <table class="ct-layout_table tr-indent2">
        <caption>Layout table for location information</caption>
        <thead>
          <tr>
            <th id="locName"></th>
            <th id="locStatus"></th>
          </tr>
        </thead>
        <tbody>
                                    <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, California</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">University of California Davis</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Sacramento, California, United States, 95817  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Indiana</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Indiana Hemophilia &amp; Thrombosis center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Indianapolis, Indiana, United States, 46260  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Michigan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">University of Michigan, C.S. Mott Children's Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Ann Arbor, Michigan, United States, 48109  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, North Carolina</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Univ of N Carolina Chapel Hill; Hematology/Oncology</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Chapel Hill, North Carolina, United States, 27514  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, Queensland</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Royal Brisbane Hospital; Clinical Haematology</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Brisbane, Queensland, Australia, 4029  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, South Australia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Royal Adelaide Hospital; Haematology Clinical Trials</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Adelaide, South Australia, Australia, 5000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Belgium</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Cliniques Universitaires St-Luc</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bruxelles, Belgium, 1200  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">UZ Leuven Gasthuisberg</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Leuven, Belgium, 3000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Japan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hokkaido University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Hokkaido, Japan, 060-8648  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Nara Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Nara, Japan, 634-8522  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">National Center for Child Health and Development</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 157-8535  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Tokyo Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 160-0023  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Poland</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Instytut Hematologii i Transfuzjologii; Klinika Zaburze&#324; Hemostazy i Chor&#243;b Wewn&#281;trznych</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Warsaw, Poland, 02-776  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotwor&#243;w Krwi i Transplantacji Szpiku</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Wroc&#322;aw, Poland, 50-367  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Spain</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Paz; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Madrid, Spain, 28046  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario Virgen del Rocio; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Sevilla, Spain, 41013  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Fe; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Valencia, Spain, 46026  </td></tr>
                                          </tbody>
      </table>
    </div>
  </div>   
  
  <!-- sponsors -->
      <div class="ct-header3" style="margin-top:2ex">Sponsors and Collaborators</div>
              <div class="tr-indent2" style="margin-top:1ex">Hoffmann-La Roche</div>
              <div class="tr-indent2" style="margin-top:1ex">Chugai Pharmaceutical</div>
        
  <!-- overall officials -->
    <div class="ct-header3" style="margin-top:2ex">Investigators</div>
  <div class="tr-table_cover">
  <table class="ct-layout_table tr-indent2">
    <caption>Layout table for investigator information</caption>
    <thead>
    <tr>
      <th id="role" style="visibility:hidden"></th>
      <th id="name" style="visibility:hidden"></th>
      <th id="affiliation" style="visibility:hidden"></th>
      <th id="address" style="visibility:hidden"></th>
    </tr>
    </thead>
        <tr>
      <td headers="role">Study Director:</td>
      <td headers="name">Clinical Trials</td>
            <td headers="affiliation">Hoffmann-La Roche</td>
            <td headers="address"></td>
    </tr>
      </table>
  </div>
  

</div>
</div>
						
<!-- more_info_section -->

<!-- Large docs section -->

    <div class="tr-indent1" style="margin-top:5ex; border:1px solid white">
    <span class="ct-header2">&nbsp; Study Documents (Full-Text)</span>

    <div class="tr-indent2">
      <br/>
      Documents provided by Hoffmann-La Roche:
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/60/NCT03020160/Prot_000.pdf" title="Study Protocol" onclick="openNewWindow('/ProvidedDocs/60/NCT03020160/Prot_000.pdf'); return false">Study Protocol</a>&nbsp; [PDF] July 25, 2017
      </div>
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/60/NCT03020160/SAP_001.pdf" title="Statistical Analysis Plan" onclick="openNewWindow('/ProvidedDocs/60/NCT03020160/SAP_001.pdf'); return false">Statistical Analysis Plan</a>&nbsp; [PDF] June 20, 2017
      </div>
                 <br/>
    </div>
  </div>
    

<!-- More info section -->
  <div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
  <div class="tr-subsection">
  	<div class="ct-header2"><a id="moreinfo"></a>More Information</div>
  	<div class="tr-underline"></div>
  	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  
  <div class="tr-indent2" style="margin-top:1em;">


    <!-- Additional Information -->
    

    <!-- Available Study Data/Document -->
    

  <!-- References -->
    
    
  <!-- Derived References -->
        <span class="ct-header3">Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):</span>
      <div class="tr-indent2">
                <div style="margin-top:2ex">
                    <a href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjER4Rxg0RA6h9Ei4L3BUgWwNG0it." title="Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jim&#233;nez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFjER4Rxg0RA6h9Ei4L3BUgWwNG0it.'); return false">Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jim&#233;nez-Yuste V. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.</a>
                            </div>
              </div>
      <br/>
    
   
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex;">
    <caption>Layout table for additonal information</caption>
    <thead>
    <tr>
      <th id="colTitle1"></th>
      <th id="colData1"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Responsible Party:</td>
      <td headers="colData1" style="padding-left:1em">Hoffmann-La Roche</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">ClinicalTrials.gov Identifier:</td>
      <td headers="colData1" style="padding-left:1em">
        <a class="tr-study-link" title="Current version of study NCT03020160 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT03020160">NCT03020160</a> &nbsp; &nbsp;

  <script type="text/javascript">
    <!--
    // Scramble access to archive site -
    // don't want crawlers directing users to outdated versions of the study
    // this should be opaque to crawlers that don't execute javascript
    var yyy=new Array(
      ['<','a clas','s="tr-study','-link c', 't-now','rap" t','itle="Hist','orical vers','ions of '],
      ['study ','NCT03020160',' on Clin','icalTrials.','go'],
      ['v Ar','chive',' Sit','e" ','onc','lick="','openN','ewWin', 'dow(','\'/ct2/', 'history/'],
      ['NCT03020160','\'); return', ' false;" '],
      ['href','="/ct2/','history/','NCT03020160"','>'],
      ['Histo','ry of C','hange','s<','/','a>']);
    var i=0;
    var j=0;
    var xxx='';
    for (i=0; i<yyy.length; i++)
      for (j=0; j<yyy[i].length; j++)
        xxx+=yyy[i][j];
    document.write(xxx)
    -->
  </script>

      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Other Study ID Numbers:</td>
      <td headers="colData1" style="padding-left:1em">
                                    BO39182 <br/>
                                                2016-001094-33 ( EudraCT Number )<br/>
                            </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">First Posted:</td>
      <td headers="colData1" style="padding-left:1em">January 13, 2017
          &nbsp;&nbsp;
          <a class="tr-study-link ct-nowrap" href="/ct2/keydates/NCT03020160"
                title="View key record dates for NCT03020160"
                onclick="openNewWindow('/ct2/keydates/NCT03020160'); return false;">Key Record Dates</a>
      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Results First Posted:</td>
      <td headers="colData1" style="padding-left:1em">December 26, 2018</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Update Posted:</td>
      <td headers="colData1" style="padding-left:1em">May 17, 2021
      </td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Verified:</td>
      <td headers="colData1" style="padding-left:1em">May 2021
      </td>
    </tr>
           
    <!-- Plan to Share Data -->
        </tbody>
  </table>

    <br/>
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex">
    <caption>Layout table for additional information</caption>
    <thead>
    <tr>
      <th id="colTitle2"></th>
      <th id="colData2"></th>
    </tr>
    </thead>
    <tbody>       
        <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Drug Product:</td>
      <td headers="colData2" style="padding-left:1em">Yes</td>
    </tr>
            <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Device Product:</td>
      <td headers="colData2" style="padding-left:1em">No</td>
    </tr>
                    </tbody>
  </table>
  
  
    <!-- keywords -->
    
    <!-- mesh terms -->
          <div class="tr-tableLabel">Additional relevant MeSH terms:</div>
      <div class="tr-indent3">
        <table class="ct-layout_table tr-meshTerms" style="width:100%;">
          <caption>Layout table for MeSH terms</caption>
          <thead>
          <tr>
            <th id="meshTermCol1" style="width:50%;"></th>
            <th id="meshTermCol2"></th>
          </tr>
          </thead>
          <tr>
            <td headers="meshTermCol1" style="padding-left:1em;">
                            Hemophilia A<br/>
                            Blood Coagulation Disorders, Inherited<br/>
                            Blood Coagulation Disorders<br/>
                            Hematologic Diseases<br/>
                          </td>
                        <td headers="meshTermCol1" style="padding-left:1em;">
                            Coagulation Protein Disorders<br/>
                            Hemorrhagic Disorders<br/>
                            Genetic Diseases, Inborn<br/>
                          </td>
                      </tr>
        </table>
      </div>
    
  <br/>

  <!--
        <span class="ct-body3">ClinicalTrials.gov processed this record on July 02, 2021</span><br/>
      -->
    <br/>  
  </div>
   </div>
						
			<div id="to-top"><a href="#wrapper">To Top</a></div>
			
			<div style="clear:both;"></div>
		</div>
	</div>
</div>  
<div>       <div id="for-footer">
        <ul class="ct-horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="ct-horz-list">
		<li><a     href="/ct2/home">Home</a></li>
		<li><a     href="/ct2/resources/rss">RSS Feeds</a></li>
		<li><a     href="/ct2/sitemap">Site Map</a></li>
		<li><a     href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
		<li><a     href="/ct2/about-site/disclaimer">Disclaimer</a></li>
		<li><a     href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03020160" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03020160'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="ct-horz-list">
		<li ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li ><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="ct-horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="/ct2/html/js/instrumentNCBIBaseJS.min.js?v=2"></script><noscript></noscript>
<script type="text/javascript" src="/ct2/html/js/main-glossary.js?v=44"></script><noscript></noscript>
<script type="text/javascript">
//OnSubmit routine - copy over some useful data and submit
function sendSearchPing() {
// Get pinger values
var cVals = ncbi.sg.getInstance()._cachedVals;
var app = cVals['ncbi_app'];
var db = cVals['ncbi_db'];
var pdid = cVals['ncbi_pdid'];
var pcid = cVals['ncbi_pcid'];
// Populate search details
var searchDetails = {};
searchDetails['jsevent'] = 'search';
searchDetails['searchtext'] = jQuery('#header-search-query').val();
if (app!=null) searchDetails['ncbi_app'] = app.value;
if (db!=null) searchDetails['ncbi_db'] = db.value;
if (pdid!=null) searchDetails['ncbi_pdid'] = pdid.value;
if (pcid!=null) searchDetails['ncbi_pcid'] = pcid.value;
// Send ping msg
ncbi.sg.ping(searchDetails);
};
</script>


</body>
</html>
